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In April 2006, 30 international experts gathered in Athens,
Greece, to discuss systemic sclerosis (SSc) and related
connective tissue diseases (CTDs). SSc is a clinically
heterogeneous and complex disease that is characterized by
vascular dysfunction, vascular and extravascular fibrosis, and
characteristic immune derangements, and for which few
treatment options are available. The aims of the CTD
International Scientific Advisory Board were threefold: to
define the role of local mediators in CTDs, in particular to
identify the nature of the initial insult in CTDs and to consider
the role of genetic perturbations in CTDs; to translate what
has been learned from clinical trials into clinical practice and
to evaluate current treatment options for CTDs and their
complications; and to address future directions for the
management of CTDs and associated rare diseases, based
on the biologic mechanisms elucidated. This supplement
provides a comprehensive review of the 2-day meeting in
order to share important insights, opinions, and clinical
approaches to management of CTDs.
The first paper in this supplement, that by Abraham and
Distler [1], reviews the potential role of endothelin (ET)-1 and
the crosstalk and interplay between the various inflammatory
mediators that lead to the vascular changes characteristic of
the pathophysiology of SSc and other CTDs. The authors
present the available evidence suggesting that ET-1 may play
a key role at the early stages of CTDs by activating fibroblasts
and pericytes. As yet, the event triggering endothelial cell
injury is unknown.
Having established that there is a need to improve our under-
standing of the factors that potentially initiate endothelial
injury, Koch and Distler [2] review the possible initiators of
vascular injury in CTDs, focusing on dysregulation of
angiogenesis as an important process in the pathogenesis of
many CTDs. While our knowledge on the role played by
angiogenesis in various CTDs has advanced significantly,
Koch and Distler point out that there are many unanswered
questions that must be addressed if we are to elucidate fully
the pathogenesis of SSc and improve its management. The
critical question is whether it will be therapeutically useful to
augment angiogenesis and whether it will be possible to
manipulate selectively the positive and negative effects of
mediators such as ET-1.
Fibrosis, caused by excessive extracellular matrix accumula-
tion, is a unifying feature of many CTDs and is a cardinal
pathologic event in SSc. Krieg, Abraham, and Lafyatis [3]
review a series of experimental studies that suggest that a
complex network of intercellular interactions involving
keratinocytes, fibroblasts, and an array of molecular
mediators drive the pathogenic events that lead to fibrosis.
Our understanding of the genetic factors that may play a role
in SSc has increased considerably in recent years; genes
have a role to play in either determining susceptibility or
influencing the phenotypic expression of the disease, or both.
The article by Mayes and Trojanowska [4] reviews the genetic
loci that appear to be associated with SSc. Genetic studies
are considerably hampered by the complexity of SSc disease.
Mayes and Trojanowska review recent evidence for the
contribution of a candidate gene, Fli1, whose dysregulation
appears to play a pathologic role in SSc skin fibrosis as well
as having an effect on vessel degeneration.
The next article, by Denton [5], reviews therapeutic targets in
SSc, their links to pathology, and the importance of crosstalk
between mediators. The relevance of the timing of inter-
vention to possible outcomes of therapeutic interventions is
discussed. Strategies for disease modification and novel
Preface
Systemic sclerosis and related connective tissue diseases:
present and future
Lewis J Rubin1, Carol M Black2, Christopher P Denton2 and James R Seibold3
1Division of Pulmonary and Critical Care Medicine, University of California, San Diego, Campus Point Drive, La Jolla, California 92037-7381, USA
2Centre for Rheumatology, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF, UK
3University of Michigan Scleroderma Program, East Medical Center Drive, Ann Arbor, Michigan 48109-0358, USA
Corresponding author: Lewis J Rubin, ljrubin@ucsd.edu
Published: 15 August 2007 Arthritis Research & Therapy 2007, 9(Suppl 2):S1 (doi:10.1186/ar2185)
This article is online at http://arthritis-research.com/content/9/S2/S1
© 2007 BioMed Central Ltd
CTD = connective tissue disease; ET = endothelin; PH = pulmonary hypertension; SSc = systemic sclerosis.Page 2 of 2
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 Suppl 2 Rubin et al.
therapeutic targets are also presented. The lack of clinical
success from targeting logical profibrotic mediators is
contrasted with positive results on vasculopathic manifesta-
tions of CTD with dual endothelin receptor antagonism.
Matucci-Cerinic, Steen, Furst, and Seibold [6] review data
from recent clinical trials and information derived from retro-
spective observational studies from databases and patient
registries. They also discuss how we may be able to use this
information to provide the best possible outcomes for
patients with SSc. The wealth of clinical information has
improved our understanding of the diverse clinical course of
the disease. Furthermore, these data can be used to refine
existing outcome measures for the design of future clinical
trials that maximize the likelihood of observing a positive
treatment effect with the drugs at our disposal. The authors
go on to discuss the results of trials in interstitial lung disease,
which underscore the need for a definitive trial design
template for studies in this patient population. In a
progressive disease such as SSc, it is becoming increasingly
clear that the greatest chance of demonstrating a disease-
modifying effect is to treat aggressively and early in the
disease process. A key challenge for the future is to identify
risk factors that will allow enrichment of clinical trial patient
populations, such that clinically relevant treatment effects can
be observed.
In his article, Baughman [7] reviews the pathophysiology of
pulmonary hypertension (PH) associated with sarcoidosis,
the role of ET-1, and the rationale behind ET-1 blockade.
There is mounting evidence to suggest that PH is a relatively
common complication of sarcoidosis, not only in patients with
end-stage pulmonary fibrosis (in whom it is predictive of
increased mortality) but also in those with earlier stage
pulmonary disease. Increased levels of ET-1 in plasma and
bronchoalveolar lavage of some sarcoid patients are
consistent with a pathogenic role in both pulmonary fibrosis
and sarcoidosis associated PH. Preliminary clinical data with
endothelin receptor antagonists in sarcoidosis are encouraging
and, in combination with anti-inflammatory medications, these
agents may provide additional clinical benefit and improve
outcomes in patients with sarcoidosis associated PH.
The next article, by Guillevin and Dörner [8], focuses on
systemic vasculitis, which is a rare and destructive
inflammatory disease of blood vessel walls that occurs in all
CTDs. This inflammatory activity is believed to contribute to
the increased risk for cardiovascular morbidity and mortality in
rheumatoid arthritis and to the accelerated atherosclerosis
seen in systemic lupus erythematosus. Endothelial cell
activation via autoantibody or immune complex binding is a
common pathogenic pathway in the systemic vasculitis
associated with both rheumatoid arthritis and systemic lupus
erythematosus, and there is evidence that ET-1 plays a role in
some clinical manifestations of vasculitis. Therefore,
endothelin receptor antagonism may be of clinical benefit in
the treatment of specific vascular manifestations of vasculitis
as an adjunct to standard therapy with glucocorticoids and
immunosuppressant agents.
In their concluding article, Rubin, Black, Denton, and Seibold
discuss future directions in the areas of SSc research and
targets for therapy [9].
In summary, the collection of articles included in this
supplement provides a review of our current understanding of
SSc and other CTDs, the pathophysiologic processes
involved, and the approach to management. Although
considerable progress has been made in recent years, we
have a long way to go. Early diagnosis and treatment with
effective therapies are key to providing patients with the best
possible long-term outcomes.
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